VYNE - VYNE Therapeutics' Zilxi topical foam 1.5% is now available nationwide

VYNE Therapeutics (VYNE) announces that its novel ZILXI (minocycline) topical foam, 1.5% is now available by prescription for the treatment of inflammatory lesions of rosacea in adults.This new once-daily therapy will be available in retail, community and specialty pharmacies nationwide. The annual list price of ZILXI will be $485 per 30-gram canister. The Company is working to align contracts with commercial insurers, expanding efforts previously undertaken for AMZEEQ, to offer the broadest possible access to ZILXI for patients and healthcare professionals.Shares up 2% premarket.

For further details see:

VYNE Therapeutics' Zilxi topical foam 1.5% is now available nationwide